Since all patients with HER2 + IBC tumours received standard anti-HER2 + targeted therapy, there was a significant positive correlation between high expression of PTN molecules and high expression of Her2, indicating that high expression of PTN molecules could be used as a molecular marker for a better therapeutic response in patients with Her2 + IBC. This evidence concerns the gene PTN and inflammatory breast carcinoma.